dglobalnews.com Do Analysts See Any Upside to Henry Schein, Inc. (NASDAQ:HSIC)?
Published: Fri, February 24, 2017
Medical | By Benjamin Edwards

Do Analysts See Any Upside to Henry Schein, Inc. (NASDAQ:HSIC)?

Do Analysts See Any Upside to Henry Schein, Inc. (NASDAQ:HSIC)?

Snyder thinks that this multiple is comparable to Henry Schein's three-year forward average PE of 23.2X. The company has a 50-day moving average price of $159.76 and a 200-day moving average price of $158.68.

Many analysts are providing their Estimated Earnings analysis for Henry Schein, Inc. and for the current quarter 13 analysts have projected that the stock could give an Average Earnings estimate of $1.85/share. Among 7 Analysts, Bottom line EPS Estimate for the current quarter is $1.59 while the top line estimate is $1.68, a key information to consider for Day Trading and investing in stocks. The company reported $1.88 EPS for the quarter, beating the analyst consensus estimate by $ 0.04.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Henry Schein, Inc.

10/11/2016 - Henry Schein, Inc. was upgraded to "buy" by analysts at Goldman Sachs. The institutional investor bought 134,838 shares of the company's stock, valued at approximately $21,976,000.

Henry Schein, Inc. had its "hold" rating reiterated by analysts at Evercore ISI. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Henry Schein, Inc. got Upgrade on 10-Jan-17 where investment firm Gabelli & Co Upgrade the stock from Hold to Buy. (The) upgraded Henry Schein from a "neutral" rating to a "buy" rating and set a $185.00 price target on the stock in a research note on Tuesday, October 11th.

Gambia's new president set for inauguration
US Department of State, Assistant Secretary of State for African Affairs, Linda Thomas-Greenfield is ecpected to be at the event. The European Union, which had cut support amid tensions with Jammeh, recently announced an $80m package of assistance.

10/06/2016 - UBS began new coverage on Henry Schein, Inc. giving the company a "buy" rating. Leerink Swann reiterated a hold rating on shares of Henry Schein in a research report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. Advisor Group Inc. raised its stake in Henry Schein by 33.9% in the third quarter. Northcoast Research analyst E. Snyder now expects that the brokerage will post earnings per share of $1.67 for the quarter, up from their prior estimate of $1.61. Sales, which grew 9.5 percent, were driven by an extra selling week, as well as, dental sales growth of 7.7 percent. "(HSIC)" was originally posted by BBNS and is the sole property of of BBNS. The company presently has an average rating of "Hold" and an average price target of $181.81. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of United States and global trademark and copyright law. The Company now has Insider ownership of 0.4 Percent and Institutional Ownership of 94 Percent.

The Melville, New York-based company said it had profit of $1.73 per share.

Henry Schein gapped open higher Tuesday and climbed during the first half hour of trade, before settling into a range. The shares were acquired at an average cost of $151.41 per share, for a total transaction of $151,410.00. Following the completion of the acquisition, the director now owns 2,039 shares in the company, valued at $308,724.99. The Company's segments include healthcare distribution, and technology and value-added services.

"We see 4.3% sales growth in '17, driven by strong growth in the Animal Health and Medical segments and improvements in the North American Dental market", the analyst told his clients in his research note.

Like this: